---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-002842"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:10:56.086276+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coherus stockholders approve UDENYCA sale to Intas Pharmaceuticals

## Summary
- Stockholders voted 70,989,067 FOR, 968,989 AGAINST, 621,431 ABSTAIN; majority threshold was 57,945,094.
- Approval clears key milestone for divestiture of UDENYCA (pegfilgrastim-cbqv) franchise under Dec 2, 2024 Asset Purchase Agreement.
- Special Meeting held virtually on March 11, 2025; 115,890,186 shares outstanding as of Jan 27, 2025 record date.

## SEC filing metadata
- accession: 0001558370-25-002842
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837025002842/0001558370-25-002842-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837025002842/chrs-20250311x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-002842
- JSON: https://secwatch.observer/filing/0001558370-25-002842.json
- Plain text: https://secwatch.observer/filing/0001558370-25-002842.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.